Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Does treatment with the insulin sensitizer metformin modify the levels and activation of proteins related to the expression of the insulin-dependent glucose transporter (GLUT4), such as adenosine monophosphate-activated protein kinase (AMPK) and myocyte enhancer factor 2A (MEF2A), in endometria from hyperinsulinemic hyperandrogenemic polycystic ovary syndrome (PCOS h-Ins) patients?]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP1007252.RAUXEVoTR3iJpnWR5qfgEL1lcyy89izP9S4I4KQ10JPvo130_assertion description "[Does treatment with the insulin sensitizer metformin modify the levels and activation of proteins related to the expression of the insulin-dependent glucose transporter (GLUT4), such as adenosine monophosphate-activated protein kinase (AMPK) and myocyte enhancer factor 2A (MEF2A), in endometria from hyperinsulinemic hyperandrogenemic polycystic ovary syndrome (PCOS h-Ins) patients?]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1007252.RAUXEVoTR3iJpnWR5qfgEL1lcyy89izP9S4I4KQ10JPvo130_provenance.
• NP552299.RAF3uPIdjKPKzSZObd-Iyt_WtQsGvREl4s8crp3dfmgFk130_assertion description "[Does treatment with the insulin sensitizer metformin modify the levels and activation of proteins related to the expression of the insulin-dependent glucose transporter (GLUT4), such as adenosine monophosphate-activated protein kinase (AMPK) and myocyte enhancer factor 2A (MEF2A), in endometria from hyperinsulinemic hyperandrogenemic polycystic ovary syndrome (PCOS h-Ins) patients?]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP552299.RAF3uPIdjKPKzSZObd-Iyt_WtQsGvREl4s8crp3dfmgFk130_provenance.
• assertion description "[Does treatment with the insulin sensitizer metformin modify the levels and activation of proteins related to the expression of the insulin-dependent glucose transporter (GLUT4), such as adenosine monophosphate-activated protein kinase (AMPK) and myocyte enhancer factor 2A (MEF2A), in endometria from hyperinsulinemic hyperandrogenemic polycystic ovary syndrome (PCOS h-Ins) patients?]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP696260.RAEXgQY81uRNlJ55CB-Sc67byS2zEnVsJrRS_HZHkB3EE130_assertion description "[Does treatment with the insulin sensitizer metformin modify the levels and activation of proteins related to the expression of the insulin-dependent glucose transporter (GLUT4), such as adenosine monophosphate-activated protein kinase (AMPK) and myocyte enhancer factor 2A (MEF2A), in endometria from hyperinsulinemic hyperandrogenemic polycystic ovary syndrome (PCOS h-Ins) patients?]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP696260.RAEXgQY81uRNlJ55CB-Sc67byS2zEnVsJrRS_HZHkB3EE130_provenance.
• NP1070496.RAWX_TipkHrnqp9xFbFQbrq98kRihl-Z4dUyb66C3gjXI130_assertion description "[Does treatment with the insulin sensitizer metformin modify the levels and activation of proteins related to the expression of the insulin-dependent glucose transporter (GLUT4), such as adenosine monophosphate-activated protein kinase (AMPK) and myocyte enhancer factor 2A (MEF2A), in endometria from hyperinsulinemic hyperandrogenemic polycystic ovary syndrome (PCOS h-Ins) patients?]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1070496.RAWX_TipkHrnqp9xFbFQbrq98kRihl-Z4dUyb66C3gjXI130_provenance.
• assertion description "[Does treatment with the insulin sensitizer metformin modify the levels and activation of proteins related to the expression of the insulin-dependent glucose transporter (GLUT4), such as adenosine monophosphate-activated protein kinase (AMPK) and myocyte enhancer factor 2A (MEF2A), in endometria from hyperinsulinemic hyperandrogenemic polycystic ovary syndrome (PCOS h-Ins) patients?]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP1070499.RAKXYM5E0RQ3NtITeLZjy9kt0CU-XCLsJj2vvlESD4hWY130_assertion description "[Does treatment with the insulin sensitizer metformin modify the levels and activation of proteins related to the expression of the insulin-dependent glucose transporter (GLUT4), such as adenosine monophosphate-activated protein kinase (AMPK) and myocyte enhancer factor 2A (MEF2A), in endometria from hyperinsulinemic hyperandrogenemic polycystic ovary syndrome (PCOS h-Ins) patients?]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1070499.RAKXYM5E0RQ3NtITeLZjy9kt0CU-XCLsJj2vvlESD4hWY130_provenance.
• NP1070500.RAFHOWVS0gO9c8XsK1FDO89aZ2JYhKaXazNuMMCy2GWR4130_assertion description "[Does treatment with the insulin sensitizer metformin modify the levels and activation of proteins related to the expression of the insulin-dependent glucose transporter (GLUT4), such as adenosine monophosphate-activated protein kinase (AMPK) and myocyte enhancer factor 2A (MEF2A), in endometria from hyperinsulinemic hyperandrogenemic polycystic ovary syndrome (PCOS h-Ins) patients?]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1070500.RAFHOWVS0gO9c8XsK1FDO89aZ2JYhKaXazNuMMCy2GWR4130_provenance.
• NP511545.RAlQf9Hx8YTBa-nYhZHtkN4bIdGkzx0cRwBTHBudNSbp0130_assertion description "[Does treatment with the insulin sensitizer metformin modify the levels and activation of proteins related to the expression of the insulin-dependent glucose transporter (GLUT4), such as adenosine monophosphate-activated protein kinase (AMPK) and myocyte enhancer factor 2A (MEF2A), in endometria from hyperinsulinemic hyperandrogenemic polycystic ovary syndrome (PCOS h-Ins) patients?]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP511545.RAlQf9Hx8YTBa-nYhZHtkN4bIdGkzx0cRwBTHBudNSbp0130_provenance.